Resources from the same session
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
Presenter: Mark Glaire
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
MiR-31-3p is a predictive biomarker of cetuximab response in FIRE3 clinical trial
Presenter: Pierre Laurent-Puig
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
Invited discussant abstracts 456O, 457O and 458O
Presenter: Chiara Cremolini
Session: Gastrointestinal tumours, colorectal 2
Resources:
Presentation
Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor
Presenter: Gunnar Folprecht
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)
Presenter: Pierre Laurent-Puig
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial
Presenter: Francois-Clement Bidard
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial
Presenter: Julien Taieb
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.